MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 

 

 

 

 

 

 

MedKoo product information:

 

  Cobimetinib (GDC-0973)

   

Description of cobimetinib:  cobimetinib, also known as GDC-0973, is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

  

MedKoo Cat#:  203185

Name:  Cobimetinib

CAS#:  934660-93-2

 

Synonym:   XL518; XL 518; XL-518; GDC-0973; cobimetinib.

   

IUPAC/Chemical name: 

(S)-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)cyclobutyl)methanone

 

Chemical structure

Theoretical analysis

 

 

 

MedKoo Cat#:  203185
Name:  Cobimetinib
CAS#:  934660-93-2

Chemical Formula: C22H22F3IN2O2

Exact Mass: 530.06781

Molecular Weight: 530.32196

Elemental Analysis: C, 49.83; H, 4.18; F, 10.75; I, 23.93; N, 5.28; O, 6.03

 

 

Availability and price:

This agent is not in stock,  which may be  available through  custom synthesis.

 

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

 

 

Information about this agent

GDC-0973 is a potent and highly selective inhibitor of MEK (Figure 1A), with a biochemical IC50 of 4.2 nM against MEK1. In biochemical assays, GDC-0973 demonstrated >100-fold selectivity for MEK when tested against a panel of >100 serine-threonine and tyrosine kinases. GDC-0973 shows strong cellular potency in a broad panel of tumor types, particularly in BRAF or KRAS mutant cancer cell lines

 

Current developer:   Genentech

 

References

1: Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2011 Nov 16. [Epub ahead of print] PubMed PMID: 22084396.


 

 

Contact MedKoo:

Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved